Concurrent weekly nedaplatin, external beam radiotherapy and high-dose-rate brachytherapy in patients with FIGO stage IIIb cervical cancer: a comparison with a cohort treated by radiotherapy alone.

Abstract

OBJECTIVES:

The aim of this study was to evaluate whether nedaplatin-based concurrent chemoradiotherapy (CCRT) using high-dose-rate intracavitary brachytherapy (HDR-ICBT) is superior to radiotherapy (RT) alone in patients with FIGO stage IIIb cervical cancer.

METHODS:

The records of 41 consecutive women treated either with nedaplatin-based CCRT using HDR-ICBT (n = 20) or RT alone (nonrandomized control group, n = 21) for stage IIIb cervical cancer were retrospectively reviewed. The activity and toxicity were compared between the two treatment groups. Progression-free survival (PFS) and overall survival (OS) were the main endpoints.

RESULTS:

The 5-year overall survival rates in the CCRT and RT groups were 65 and 33.3%, respectively. The median OS of the CCRT and RT groups were 60 and 29 months, respectively. CCRT was significantly superior to RT alone with regard to PFS (p = 0.0015) and OS (p = 0.0364). The frequency of acute grade 3-4 toxicity was significantly higher in the CCRT group than in the RT group. However, no statistically significant difference was observed with regard to severe late toxicity.

CONCLUSIONS:

Nedaplatin-based concurrent chemoradiotherapy was safely performed and significantly improved the prognosis of patients with FIGO stage IIIb cervical cancer. This treatment can be considered as an alternative to cisplatin-based chemoradiotherapy in this patient population.

• Authors: Seiji Mabuchi, Hiromi Ugaki, Fumiaki Isohashi, Yasuo Yoshioka, Kumiko Temma, Namiko Yada-Hashimoto, Takashi Takeda, Toshiya Yamamoto, Kiyoshi Yoshino, Ryuichi Nakajima, Chie Kuragaki, Kenichirou Morishige, Takayuki Enomoto, Takehiro Inoue, Tadashi Kimura
• Journal: Gynecologic and obstetric investigation (Gynecol Obstet Invest) Vol. 69 Issue 4 Pg. 224-32 ( 2010) ISSN: 1423-002X [Electronic] Switzerland
• PMID: 20068328 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright (c) 2010 S. Karger AG, Basel.

Chemical References

• Antineoplastic Agents
• Organoplatinum Compounds
• nedaplatin

Topics

• Aged
• Antineoplastic Agents (administration & dosage)
• Brachytherapy (adverse effects)
• Carcinoma, Squamous Cell (drug therapy, pathology, radiotherapy)
• Combined Modality Therapy (adverse effects)
• Disease-Free Survival
• Female
• Humans
• Middle Aged
• Neoplasm Staging
• Organoplatinum Compounds (administration & dosage, adverse effects)
• Retrospective Studies
• Treatment Outcome
• Uterine Cervical Neoplasms (drug therapy, pathology, radiotherapy)